Merck has completed its acquisition of CN201, a bispecific antibody from Curon Biopharmaceutical, aimed at treating relapsed or refractory non-Hodgkin lymphoma and B-cell acute lymphocytic leukemia.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.